EarningsQ2 2026 Earnings Report
MX:RYTM Q2 2026 EPS Results
Actual EPS-$12.60
Consensus EPS-$13.93
Beat/MissBeat by +$1.33
One Year Ago EPS-$12.95
MX:RYTM Q2 2026 Revenue Results
Actual Revenue$1.23B
Expected Revenue$1.17B
Beat/MissBeat by +$62.10M
YoY Revenue Growth+46.91%
Earnings Announcement Details
QuarterQ2 2026
Date08/04/2026
TimeBefore Open
Conference CallTuesday, August 4, 2026
MX:RYTM Upcoming Earnings
Rhythm Pharmaceuticals's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:RYTM Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a largely positive commercial and scientific momentum: robust early U.S. launch metrics for IMCIVREE in acquired hypothalamic obesity, 19% sequential product sales growth, encouraging RM-718 early efficacy comparable to existing MC4R agonists, NEJM coverage, and planned international rollouts (Japan and Europe). Key challenges include a one‑time France revenue charge, higher SG&A and continued GAAP losses, some tolerability-related discontinuations in RM-718, and ongoing diagnosis/access constraints that could temper uptake timing. On balance, the growth and pipeline derisking signals materially outweigh the near-term financial and operational headwinds.Company Guidance
Strong U.S. IMCIVREE HO Launch Activity
Received >400 start forms from ~300 prescribers in the first 14 weeks after FDA approval (March 19), ~300 unique prescribers activated, ~20% of prescribers wrote >1 script; 65% of priority accounts activated and ~25% of prescriptions came from those accounts.
Sequential Revenue Growth
Global net product sales of IMCIVREE totaled $71.3M in Q2 2026, a 19% sequential increase from $60.1M in Q1 2026; U.S. accounted for $51M (72% of product revenue).
Increase in Patients on Reimbursed Therapy
Patients on reimbursed therapy grew >20% quarter-over-quarter, driven by the acquired HO launch and continued BBS growth ex-U.S.
Positive Early Payer Experience
By end of Q2 secured positive HO policies covering ~25% of Medicaid covered lives and ~35% of commercial covered lives; many initial approvals obtained at the prior authorization stage even without HO-specific policies in place.
RM-718 Phase II Early Efficacy and Tolerability
In 7 patients reaching week 16, RM-718 produced a mean BMI reduction of 11.6% (week 16), comparing favorably to setmelanotide pooled HO week 16 reduction (10.1%) and bivamelagon week 14 (10.1%); no generalized hyperpigmentation observed.
NEJM Publication and Scientific Recognition
Phase III HO TRANSCEND trial results published in the New England Journal of Medicine with an accompanying editorial, increasing disease and therapy awareness among clinicians, researchers and payers.
Regulatory and Geographic Expansion
European Commission granted marketing authorization for IMCIVREE for acquired HO in May; Japan approval and launch anticipated by year-end 2026; European country launches (Germany H1 2027, others 2027) are planned.
Solid Cash Position and Runway
Ended Q2 with approximately $331M in cash, cash equivalents and short-term investments, which the company expects will fund operations for at least 24 months.
Updated 2026 Non-GAAP OpEx Guidance
Updated full-year non-GAAP operating expense guidance of $363M–$397M with R&D $175M–$195M (midpoint reduced by $20M due to CMC timing shifts) and non-GAAP SG&A $188M–$202M (unchanged).
Clinical Progress in Prader-Willi and Program Plans
Presented positive 6-month PWS data at ENDO showing clinically meaningful BMI and BMI-Z score reductions, fat mass reduction, lean mass preservation and improvements in hyperphagia and anxiety; PWS Part D enrollment for RM-718 to complete by year-end (goal 10–15 patients) and bivamelagon Phase III in RH planned to start by year-end.
MX:RYTM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed